Women who had the variation of a gene called as Neuregulin 3 are more likely to gain relief from consuming a painkiller, gabapentin. Using this drug as a treatment option for the patients with this gene could prevent the ineffective treatment and the unavoidable side effects. The research could help improve further the uses of this drug in treating chronic pelvic pain. These findings by the University of Edinburgh, were a follow-up to a previous study which suggested that gabapentin performed well on certain patients.
In their newest study, that was a collaboration with the University of Oxford, where they had discovered that in 71 women suffering from chronic pelvic pain, among those who had received gabapentin, 29 had a response whereas 42 had no improvement. These findings delve into the underlying mechanisms behind chronic pain. The team does acknowledge that more research is required to be done in a larger population of women for confirmation. The study is published in the journal iScience. Their research is supported by Edinburgh Innovations (EI). The study’s lead author, Dr Scott Mackenzie, University of Edinburgh for Reproductive Health states, “A genetic factor that can predict how well gabapentin will work inpatients offers the prospect of tailored treatment, and provides invaluable insights into understanding chronic pain. We hope eventually to use this genetic marker to optimise personalised treatment decisions and minimise adverse effects for women with chronic pelvic pain.”
The EI’s Head of Business Development for the College of Medicine and Veterinary Medicine, Dr Susan Bodie, adds “Isolating this single genetic marker is an important discovery that could ultimately help refine treatments for millions of women worldwide who suffer from chronic pelvic pain, as well as increasing our understanding of its role in other pain conditions. We believe this an exciting opportunity for collaboration with a commercial partner who can help translate the research into a clinical setting.”







Leave a comment